DE2611690A1
(de)
*
|
1976-03-19 |
1977-09-22 |
Goedecke Ag |
Cyclische sulfonyloxyimide
|
US4876279A
(en)
*
|
1986-05-05 |
1989-10-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4894476A
(en)
*
|
1988-05-02 |
1990-01-16 |
Warner-Lambert Company |
Gabapentin monohydrate and a process for producing the same
|
US4960931A
(en)
*
|
1988-05-02 |
1990-10-02 |
Warner-Lambert Company |
Gabapentin mohohydrate and a process for producing the same
|
YU162789A
(en)
*
|
1988-09-01 |
1990-12-31 |
Lonza Ag |
2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
|
DE3928184A1
(de)
*
|
1989-08-25 |
1991-02-28 |
Goedecke Ag |
Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
|
US5319135A
(en)
*
|
1989-08-25 |
1994-06-07 |
Warner-Lambert Company |
Process for cyclic amino acid anticonvulsant compounds
|
US5132451A
(en)
*
|
1989-08-25 |
1992-07-21 |
Warner-Lambert Company |
Process for cyclic amino acid anticonvulsant compounds
|
PH27359A
(en)
*
|
1989-08-25 |
1993-06-21 |
Warner Lambert Co |
Process for cyclic amino acid anticonvulsant compounds
|
DE3928183A1
(de)
*
|
1989-08-25 |
1991-02-28 |
Goedecke Ag |
Lactamfreie cyclische aminosaeuren
|
DE3928182A1
(de)
*
|
1989-08-25 |
1991-02-28 |
Goedecke Ag |
Verfahren zur herstellung von gabapentin
|
US5149870A
(en)
*
|
1989-11-16 |
1992-09-22 |
Lonza Ltd. |
Process for the production of 1-(aminomethyl)cyclohexane acetic acid
|
US5157138A
(en)
*
|
1989-11-16 |
1992-10-20 |
Pfizer, Inc. |
Glutaric acid derivatives and preparation thereof
|
US5136091A
(en)
*
|
1989-11-16 |
1992-08-04 |
Lonza Ltd. |
Process for the production of 1-(aminomethyl) cyclohexane acetic acid
|
GB8925933D0
(en)
*
|
1989-11-16 |
1990-01-04 |
Pfizer Ltd |
Glutaric acid derivatives and preparation thereof
|
US5260467A
(en)
*
|
1989-11-16 |
1993-11-09 |
Pfizer Inc. |
Glutaric acid derivatives and preparation thereof
|
FI905584A
(fi)
*
|
1989-11-16 |
1991-05-17 |
Lonza Ag |
Foerfarande foer framstaellning av 1-(aminometyl)cyklohexanaettikssyra.
|
US5084479A
(en)
*
|
1990-01-02 |
1992-01-28 |
Warner-Lambert Company |
Novel methods for treating neurodegenerative diseases
|
US5025035A
(en)
*
|
1990-10-12 |
1991-06-18 |
Warner-Lambert Company |
Method of treating depression
|
US5792796A
(en)
*
|
1994-07-27 |
1998-08-11 |
Warner-Lambert Company |
Methods for treating anxiety and panic
|
US5510381A
(en)
*
|
1995-05-15 |
1996-04-23 |
Warner-Lambert Company |
Method of treatment of mania and bipolar disorder
|
SK282665B6
(sk)
*
|
1996-02-07 |
2002-11-06 |
Warner-Lambert Company |
Cyklická aminokyselina a farmaceutický prostriedok na jej báze
|
IL125544A
(en)
*
|
1996-03-14 |
2002-03-10 |
Warner Lambert Co |
Transformed cyclic amino acids and pharmaceutical preparations containing them
|
DE69709070T2
(de)
*
|
1996-03-14 |
2002-06-20 |
Warner Lambert Co |
Verbrückte zyklische aminosäuren als pharmazeutische mittel
|
USRE41920E1
(en)
|
1996-07-24 |
2010-11-09 |
Warner-Lambert Company Llc |
Isobutylgaba and its derivatives for the treatment of pain
|
DE69737719D1
(de)
*
|
1996-10-23 |
2007-06-21 |
Warner Lambert Co |
Substituierte gamma-aminobuttersäurederivate als arzneimittel
|
IL119890A
(en)
*
|
1996-12-24 |
2002-03-10 |
Teva Pharma |
Gabapentin form iii and preparation of gabapentin form ii
|
US6255526B1
(en)
|
1996-12-24 |
2001-07-03 |
Teva Pharmaceutical Industries Ltd. |
Preparation of gabapentin
|
US6329429B1
(en)
|
1997-06-25 |
2001-12-11 |
Warner-Lambert Company |
Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
|
HRP980342A2
(en)
*
|
1997-06-25 |
1999-02-28 |
Warner Lambert Co |
Anti-inflammatory method
|
AU9019198A
(en)
|
1997-08-19 |
1999-03-08 |
Warner-Lambert Company |
Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
|
DE69832712T2
(de)
*
|
1997-09-08 |
2006-06-22 |
Warner-Lambert Company Llc |
Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
|
AU9318398A
(en)
|
1997-10-07 |
1999-04-27 |
Warner-Lambert Company |
Process for preparing a cyclic amino acid anticonvulsant compound
|
GEP20094817B
(en)
*
|
1997-10-27 |
2009-11-10 |
Warner Lambert Co |
Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
|
US6984659B2
(en)
*
|
1997-11-18 |
2006-01-10 |
Klinikum Der Albert-Ludwigs Universitaet |
2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
|
JP2002508352A
(ja)
|
1997-12-16 |
2002-03-19 |
ワーナー−ランバート・カンパニー |
4(3)置換−4(3)−アミノメチル−(チオ)ピラン又はピペリジン誘導体(=ガバペンチン類似体)、それらの製法および神経病理学的疾患の治療における使用
|
NZ503963A
(en)
|
1997-12-16 |
2002-09-27 |
Warner Lambert Co |
1-substituted-1-aminomethyl-cycloalkane derivatives, or gabapentin analogues, preparation and use in the treatment of neurological disorders
|
WO1999031074A2
(en)
|
1997-12-16 |
1999-06-24 |
Warner-Lambert Company |
((cyclo)alkyl substituted)-.gamma.-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders
|
WO1999037296A1
(en)
*
|
1998-01-23 |
1999-07-29 |
Warner-Lambert Company |
Gabapentin and its derivatives for the treatment of muscular and skeletal pain
|
EP0974351A3
(en)
*
|
1998-04-24 |
2000-12-13 |
Jouveinal |
Medicament for preventing and treating gastrointestinal damage
|
AU769038B2
(en)
*
|
1998-05-15 |
2004-01-15 |
Warner-Lambert Company Llc |
Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
|
HU228771B1
(en)
|
1998-05-15 |
2013-05-28 |
Warner Lambert Co |
Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
|
ES2137137B1
(es)
*
|
1998-05-25 |
2000-08-16 |
Medichem Sa |
Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
|
US6316638B1
(en)
|
1998-05-26 |
2001-11-13 |
Warner-Lambert Company |
Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
|
ITMI981535A1
(it)
*
|
1998-07-03 |
2000-01-03 |
Zambon Spa |
Processo per la preparazione di gabapentina
|
US20030045500A1
(en)
*
|
1998-07-09 |
2003-03-06 |
Leslie Magnus |
Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
|
FR2781793B1
(fr)
|
1998-08-03 |
2001-07-20 |
Prographarm Lab |
Procede de fabrication de granules de gabapentine enrobes
|
HU225502B1
(en)
*
|
1998-12-29 |
2007-01-29 |
Richter Gedeon Vegyeszet |
Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
|
IT1311984B1
(it)
|
1999-03-26 |
2002-03-22 |
Bioindustria Lab Italiano Medi |
Procedimento per la preparzione di gabapentin.
|
EP1169060B1
(en)
*
|
1999-04-09 |
2005-08-31 |
Euro-Celtique S.A. |
Sodium channel blocker compositions and the use thereof
|
US6710190B1
(en)
|
1999-05-28 |
2004-03-23 |
Warner-Lambert Company |
3-heteroarylalkyl substituted gaba analogs
|
AU4673200A
(en)
*
|
1999-05-28 |
2000-12-18 |
Warner-Lambert Company |
3-heteroarylalkyl substituted gaba analogs
|
US20080207755A1
(en)
*
|
2000-05-31 |
2008-08-28 |
Pfizer Inc |
Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
|
US7164034B2
(en)
*
|
1999-06-10 |
2007-01-16 |
Pfizer Inc. |
Alpha2delta ligands for fibromyalgia and other disorders
|
CZ301608B6
(cs)
*
|
1999-06-10 |
2010-04-28 |
Warner-Lambert Company |
Derivát 3-propyl gamma-aminomáselné kyseliny a farmaceutický prostredek s jeho obsahem
|
US6294198B1
(en)
|
1999-08-24 |
2001-09-25 |
Purepac Pharmaceutical Co. |
Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
|
HN2000000224A
(es)
*
|
1999-10-20 |
2001-04-11 |
Warner Lambert Co |
Aminoacidos biciclicos como agentes farmaceuticos
|
GB2362646A
(en)
*
|
2000-05-26 |
2001-11-28 |
Warner Lambert Co |
Cyclic amino acid derivatives useful as pharmaceutical agents
|
US6531509B2
(en)
|
2000-06-16 |
2003-03-11 |
Teva Pharmaceutical Industries Ltd. |
Stable gabapentin containing more than 20 ppm of chlorine ion
|
EP1384473A1
(en)
*
|
2000-06-16 |
2004-01-28 |
Teva Pharmaceutical Industries Ltd. |
Stable gabapentin containing more than 20 ppm of chlorine ion
|
JP2003535885A
(ja)
*
|
2000-06-16 |
2003-12-02 |
テバ ファーマシューティカル インダストリーズ リミティド |
制御された範囲内にpHを持つ安定なギャバペンチン
|
KR100785182B1
(ko)
*
|
2000-06-26 |
2007-12-11 |
워너-램버트 캄파니 엘엘씨 |
수면 장애를 위한 가바펜틴 유사체
|
GB2364049A
(en)
*
|
2000-06-28 |
2002-01-16 |
Warner Lambert Co |
Cyclic ketones and their use in the synthesis of amino acids
|
JP2004509101A
(ja)
*
|
2000-09-14 |
2004-03-25 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
β−チオ−アミノ酸類
|
WO2002032376A2
(en)
*
|
2000-10-06 |
2002-04-25 |
Xenoport, Inc. |
Bile-acid conjugates for providing sustained systemic concentrations of drugs
|
WO2002028881A1
(en)
*
|
2000-10-06 |
2002-04-11 |
Xenoport, Inc. |
Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
|
US6620829B2
(en)
*
|
2000-10-17 |
2003-09-16 |
Warner-Lambert Company |
Method of treating noninflammatory cartilage damage
|
IT1319234B1
(it)
*
|
2000-10-23 |
2003-09-26 |
Zambon Spa |
Processo di preparazione di gabapentina.
|
GB2368579A
(en)
*
|
2000-10-31 |
2002-05-08 |
Parke Davis & Co Ltd |
Azole pharmaceutical agents
|
SK6372003A3
(en)
*
|
2000-11-02 |
2003-12-02 |
Teva Pharma |
Improved process for production of gabapentin intermediate
|
AP2001002360A0
(en)
*
|
2000-11-30 |
2001-12-31 |
Pfizer Prod Inc |
Combination of gaba agonists and sorbitol dehydrogenase inhibitors.
|
AU2002215160A1
(en)
*
|
2000-11-30 |
2002-06-11 |
Pfizer Products Inc. |
Combination of gaba agonists and aldose reductase inhibitors
|
IT1319674B1
(it)
*
|
2000-12-01 |
2003-10-23 |
Erregierre Spa |
Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
|
US20040063994A1
(en)
*
|
2001-03-16 |
2004-04-01 |
Paolo Rossi |
Process for the preparation of cyclic amino acids
|
ITMI20011132A1
(it)
|
2001-05-29 |
2002-11-29 |
Procos Spa |
Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
|
US8048917B2
(en)
|
2005-04-06 |
2011-11-01 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
EP1404324B2
(en)
*
|
2001-06-11 |
2011-04-06 |
XenoPort, Inc. |
Prodrugs of gaba analogs, compositions and uses thereof
|
US7232924B2
(en)
*
|
2001-06-11 |
2007-06-19 |
Xenoport, Inc. |
Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US7186855B2
(en)
*
|
2001-06-11 |
2007-03-06 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US7420002B2
(en)
*
|
2001-06-11 |
2008-09-02 |
Xenoport |
Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
|
IL144066A0
(en)
*
|
2001-06-28 |
2002-04-21 |
Bromine Compounds Ltd |
Process for the preparation of 1,1-cyclohexane diacetic monoamide
|
ITMI20011772A1
(it)
|
2001-08-10 |
2003-02-10 |
A M S A Anonima Materie Sint E |
Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
|
JP4350508B2
(ja)
*
|
2001-09-03 |
2009-10-21 |
ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー |
ガバペンチンまたはその類似体とα−アミノアミドとを含む薬剤組成物およびその鎮痛用途
|
US6800782B2
(en)
*
|
2001-10-09 |
2004-10-05 |
Warner-Lambert Co. |
Anhydrous crystalline forms of gabapentin
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
US20070184104A1
(en)
*
|
2001-10-25 |
2007-08-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
US20060159743A1
(en)
*
|
2001-10-25 |
2006-07-20 |
Depomed, Inc. |
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
ITMI20012750A1
(it)
|
2001-12-21 |
2003-06-21 |
Procos Spa |
Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
|
US20030119908A1
(en)
*
|
2001-12-21 |
2003-06-26 |
Zambon Group S.P.A. |
Stable gabapentin compositions
|
PL371944A1
(en)
*
|
2002-01-31 |
2005-07-11 |
Warner-Lambert Company Llc |
Alpha 2 delta ligands to treat tinnitus
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
WO2003077902A1
(en)
*
|
2002-02-19 |
2003-09-25 |
Xenoport, Inc. |
Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
|
WO2003080588A1
(en)
*
|
2002-03-20 |
2003-10-02 |
Xenoport |
Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
|
AU2003262383A1
(en)
*
|
2002-04-16 |
2003-11-03 |
Taro Pharmaceutical Industries Ltd. |
Process for preparing gabapentin
|
EP1549323A2
(en)
*
|
2002-05-07 |
2005-07-06 |
A & D Bioscience, Inc. |
Conjugates comprising central nervous system active drug
|
US7183259B2
(en)
*
|
2002-05-17 |
2007-02-27 |
Xenoport |
Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
|
PL375090A1
(en)
*
|
2002-06-27 |
2005-11-14 |
Warner-Lambert Company Llc |
Method of treating attention deficit hyperactivity disorder
|
CA2395931A1
(en)
*
|
2002-08-07 |
2004-02-07 |
Bernard Charles Sherman |
Solid compositions comprising gabapentin having improved stability
|
US7053122B2
(en)
*
|
2002-08-09 |
2006-05-30 |
Pfizer Inc |
Therapeutic use of aryl amino acid derivatives
|
US7419981B2
(en)
*
|
2002-08-15 |
2008-09-02 |
Pfizer Inc. |
Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
|
US20040092522A1
(en)
*
|
2002-08-15 |
2004-05-13 |
Field Mark John |
Synergistic combinations
|
US20040092591A1
(en)
*
|
2002-08-15 |
2004-05-13 |
Blakemore David Clive |
Therapeutic use of fused bicyclic or tricyclic amino acids
|
US20040092498A1
(en)
*
|
2002-08-16 |
2004-05-13 |
David Blakemore |
Substituted glycine derivatives for use as medicaments
|
ITMI20022071A1
(it)
*
|
2002-10-01 |
2004-04-02 |
Erregierre Spa |
Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato.
|
US7659305B2
(en)
*
|
2002-10-31 |
2010-02-09 |
Pfizer Inc. |
Therapeutic proline derivatives
|
CA2472815A1
(en)
*
|
2002-11-18 |
2004-06-03 |
Nicholas Piramal India Limited |
Improved process for preparation of gabapentin
|
PT1599446E
(pt)
*
|
2002-11-20 |
2009-11-06 |
Hikal Ltd |
Um processo melhorado para a preparação de gabalactama
|
WO2004053192A1
(en)
*
|
2002-12-11 |
2004-06-24 |
Xenoport, Inc. |
Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
|
US7060727B2
(en)
*
|
2002-12-11 |
2006-06-13 |
Xenoport, Inc. |
Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
|
US20040180958A1
(en)
*
|
2002-12-13 |
2004-09-16 |
Taylor Charles Price |
Method of treatment
|
CA2505788A1
(en)
*
|
2002-12-13 |
2004-07-01 |
Warner-Lambert Company Llc |
Pregabalin derivatives for the treatment of fibromyalgia and other disorders
|
CA2451267A1
(en)
*
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
CA2509605C
(en)
|
2002-12-13 |
2010-10-05 |
Warner-Lambert Company Llc |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
AU2003283718A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Warner-Lambert Company Llc |
Gabapentin analogues for fibromyalgia and other related disorders
|
EP1572187A1
(en)
*
|
2002-12-13 |
2005-09-14 |
Warner-Lambert Company LLC |
Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders
|
GB0301143D0
(en)
*
|
2003-01-17 |
2003-02-19 |
Amedis Pharm Ltd |
Compounds and their use
|
JP2006516275A
(ja)
*
|
2003-01-22 |
2006-06-29 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
シクロプロピルβ−アミノ酸誘導体
|
JP2006519831A
(ja)
*
|
2003-03-07 |
2006-08-31 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
テトラゾール及びオキサジアゾロン置換β−アミノ酸誘導体
|
WO2004093867A2
(en)
*
|
2003-03-25 |
2004-11-04 |
Kiel Laboratories, Inc. |
Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use
|
WO2004093866A1
(en)
*
|
2003-03-25 |
2004-11-04 |
Kiel Laboratories, Inc. |
Process for preparing phenolic acid salts of gabapentin
|
WO2004093827A2
(en)
*
|
2003-03-25 |
2004-11-04 |
Kiel Laboratories, Inc. |
Phenolic acid salts of gabapentin in solid dosage forms and methods of use
|
EP1608357A4
(en)
*
|
2003-03-31 |
2008-03-26 |
Xenoport Inc |
TREATMENT OR PREVENTION OF HITZEWALLUNGEN USING PRODRUGS OF GABA ANALOGUE
|
US20040214893A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Matthew Peterson |
Gabapentin compositions
|
ITMI20030825A1
(it)
*
|
2003-04-18 |
2004-10-19 |
Farchemia Srl |
Procedimento per la preparazione di gabapentin esente da
|
WO2004093780A2
(en)
*
|
2003-04-21 |
2004-11-04 |
Matrix Laboratories Ltd |
Process for the preparation of gabapentin form-ii
|
JP2006528676A
(ja)
*
|
2003-05-16 |
2006-12-21 |
ファイザー・プロダクツ・インク |
非定形型抗精神病薬と、gaba調節薬及び/又は抗痙攣薬の治療上の組合せ
|
MXPA05013754A
(es)
*
|
2003-06-19 |
2006-03-08 |
Pfizer Prod Inc |
Una preparacion biocatalitica del acido 1-cianociclohexanoacetico.
|
US7169812B2
(en)
*
|
2003-07-01 |
2007-01-30 |
Medtronic, Inc. |
Process for producing injectable gabapentin compositions
|
EP1680125A1
(en)
*
|
2003-07-02 |
2006-07-19 |
Warner-Lambert Company LLC |
Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
|
US20050013863A1
(en)
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
WO2005046566A2
(en)
*
|
2003-08-04 |
2005-05-26 |
Sun Pharmaceutical Industries Limited |
Stable gabapentin containing composition
|
US20050043407A1
(en)
*
|
2003-08-22 |
2005-02-24 |
Pfizer Inc |
Pharmaceutical composition for the prevention and treatment of addiction in a mammal
|
EP1670451A4
(en)
*
|
2003-09-11 |
2009-10-21 |
Xenoport Inc |
TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
|
EP1675582A1
(en)
*
|
2003-09-12 |
2006-07-05 |
Warner-Lambert Company LLC |
Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
|
MXPA06002789A
(es)
|
2003-09-12 |
2006-06-14 |
Pfizer |
Combinaciones que comprenden ligandos alfa-2-delta.
|
BRPI0414481A
(pt)
*
|
2003-09-17 |
2006-11-14 |
Xenoport Inc |
métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
|
KR101096480B1
(ko)
*
|
2003-10-14 |
2011-12-20 |
제노포트 인코포레이티드 |
감마-아미노부티르산 유사체의 결정질 형태
|
ITMI20032165A1
(it)
*
|
2003-11-11 |
2005-05-12 |
Zambon Spa |
Processo di preparazione di gabapentina
|
EP1691811B1
(en)
|
2003-12-11 |
2014-07-23 |
Sunovion Pharmaceuticals Inc. |
Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
JP2007537151A
(ja)
*
|
2004-01-29 |
2007-12-20 |
ファイザー・プロダクツ・インク |
γ−アミノ酪酸モジュレータと5−HT1B受容体アンタゴニストとの組合せ
|
US20050187295A1
(en)
*
|
2004-02-19 |
2005-08-25 |
Surendra Kalyan |
Processes for the preparation of gabapentin
|
CA2570255A1
(en)
*
|
2004-03-17 |
2005-09-22 |
Hikal Limited |
4-t-butylgabapentin and its synthesis
|
ITMI20040579A1
(it)
*
|
2004-03-25 |
2004-06-25 |
Zambon Spa |
Processo di preparazione di gabapentina
|
EP1737473A4
(en)
*
|
2004-04-19 |
2009-08-26 |
Noven Therapeutics Llc |
COMBINATIONS OF LITHIUM AND USES THEREOF
|
KR20070029740A
(ko)
*
|
2004-06-09 |
2007-03-14 |
화이자 인코포레이티드 |
통증 치료를 위한 레복세틴의 용도
|
GB0416228D0
(en)
*
|
2004-07-20 |
2004-08-25 |
Sandoz Ind Products S A |
Process for the preparation of gabapentin
|
GB0419849D0
(en)
*
|
2004-09-07 |
2004-10-13 |
Pfizer Ltd |
Pharmaceutical combination
|
BRPI0515154A
(pt)
*
|
2004-09-10 |
2008-07-08 |
Newron Pharm Spa |
uso de (halobenzilóxi)benzilamino-propanamidas para a fabricação de medicamentos ativos, compostos e composição farmacêutica
|
BRPI0517227B8
(pt)
*
|
2004-11-04 |
2021-05-25 |
Xenoport Inc |
comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス,インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
US7851498B2
(en)
*
|
2005-09-23 |
2010-12-14 |
Janssen Pharmaceutica Nv |
Hexahydro-cyclooctyl pyrazole cannabinoid modulators
|
KR20080050511A
(ko)
*
|
2005-09-23 |
2008-06-05 |
얀센 파마슈티카 엔.브이. |
테트라하이드로-사이클로펜틸 피라졸 카나비노이드모듈레이터
|
DK1937259T3
(da)
*
|
2005-09-23 |
2012-02-13 |
Janssen Pharmaceutica Nv |
Hexahydro-cycloheptapyrazol-cannabinoid-modulatorer
|
US8378096B2
(en)
*
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
US8378117B2
(en)
*
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
US7825151B2
(en)
*
|
2005-09-23 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Hexahydro-cyclooctyl pyrazole cannabinoid modulators
|
CA2625153A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
US20070112017A1
(en)
*
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
US20070117858A1
(en)
*
|
2005-11-23 |
2007-05-24 |
Mingde Xia |
Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
|
US20090176882A1
(en)
*
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
WO2007092456A2
(en)
*
|
2006-02-03 |
2007-08-16 |
Rolls-Royce Corporation |
Gas turbine engine fuel system with fuel metering valve
|
EP1820502A1
(en)
|
2006-02-10 |
2007-08-22 |
Laboratorios Del Dr. Esteve, S.A. |
Active substance combination comprising azolylcarbinol compounds
|
WO2007095513A1
(en)
*
|
2006-02-14 |
2007-08-23 |
Janssen Pharmaceutica, Nv |
Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators
|
CA2640402C
(en)
*
|
2006-03-06 |
2012-01-03 |
Pfizer Products Inc. |
Alpha-2-delta ligands for non-restorative sleep
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US8012957B2
(en)
*
|
2006-03-27 |
2011-09-06 |
Janssen Pharmaceutica Nv |
Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
|
US20070254911A1
(en)
*
|
2006-03-27 |
2007-11-01 |
Mingde Xia |
Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
|
US7678808B2
(en)
|
2006-05-09 |
2010-03-16 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
EP2377531A2
(en)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US7442834B2
(en)
*
|
2006-06-12 |
2008-10-28 |
Zhejiang Chiral Medicine Chemicals Co., Ltd. |
Process suitable for industrial scale production of gabapentin
|
EP2038249B1
(en)
*
|
2006-06-30 |
2013-09-11 |
ZaCh System S.p.A. |
Process for preparing gabapentin
|
WO2008030651A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
BRPI0720252A2
(pt)
*
|
2006-12-08 |
2014-01-07 |
Xenoport Inc |
Uso de pró-fármacos de análogos de gaba para tratar doenças
|
KR20090092307A
(ko)
|
2006-12-22 |
2009-08-31 |
레코르다티 아일랜드 리미티드 |
하요도 장애에 대한 α2δ 리간드 및 NSAIDs의 복합 치료
|
WO2008111096A2
(en)
*
|
2007-03-15 |
2008-09-18 |
Sun Pharma Advanced Research Company Ltd |
Novel prodrugs
|
WO2008157408A2
(en)
*
|
2007-06-15 |
2008-12-24 |
Xenoport, Inc. |
Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
|
US7943653B2
(en)
*
|
2007-08-13 |
2011-05-17 |
Janssen Pharmaceutica N.V. |
Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
|
US20090062392A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched gabapentin
|
WO2009061934A1
(en)
*
|
2007-11-06 |
2009-05-14 |
Xenoport, Inc. |
Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
|
EP2250148B1
(en)
*
|
2008-01-25 |
2016-08-17 |
XenoPort, Inc. |
Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
|
CA2706575C
(en)
*
|
2008-01-25 |
2015-07-14 |
Xenoport, Inc. |
Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
|
US7868043B2
(en)
|
2008-01-25 |
2011-01-11 |
Xenoport, Inc. |
Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
|
EP2116539A1
(en)
|
2008-04-25 |
2009-11-11 |
Laboratorios Del. Dr. Esteve, S.A. |
1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
|
US20100190752A1
(en)
*
|
2008-09-05 |
2010-07-29 |
Gruenenthal Gmbh |
Pharmaceutical Combination
|
AU2009302241B2
(en)
*
|
2008-10-08 |
2015-10-29 |
Xgene Pharmaceutical Inc. |
GABA conjugates and methods of use thereof
|
EP2400989B1
(en)
|
2009-02-24 |
2016-08-10 |
Nektar Therapeutics |
Gabapentin-peg conjugates
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US20110124705A1
(en)
*
|
2009-11-24 |
2011-05-26 |
Xenoport, Inc. |
Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
|
US20110130454A1
(en)
*
|
2009-11-24 |
2011-06-02 |
Xenoport, Inc. |
Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
|
WO2011071995A2
(en)
|
2009-12-08 |
2011-06-16 |
Case Western Reserve University |
Compounds and methods of treating ocular disorders
|
EP2353591A1
(en)
|
2010-02-04 |
2011-08-10 |
Laboratorios Del. Dr. Esteve, S.A. |
Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
|
EP2368872A1
(en)
|
2010-03-25 |
2011-09-28 |
Serichim S.r.l. |
Process for the preparation of Gabapentin
|
EP2388005A1
(en)
|
2010-05-21 |
2011-11-23 |
Laboratorios Del. Dr. Esteve, S.A. |
Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
|
IN2012MN02923A
(US06168655-20010102-C00055.png)
|
2010-06-01 |
2015-06-05 |
Rubicon Res Private Ltd |
|
US8431739B2
(en)
|
2010-06-14 |
2013-04-30 |
Divi's Laboratories, Ltd. |
Process for the preparation of gabapentin
|
CA2805371C
(en)
|
2010-07-30 |
2017-10-31 |
Toray Industries, Inc. |
Therapeutic agent or prophylactic agent for neuropathic pain
|
EP2415471A1
(en)
|
2010-08-03 |
2012-02-08 |
Laboratorios Del. Dr. Esteve, S.A. |
Use of sigma ligands in opioid-induced hyperalgesia
|
JP2013216580A
(ja)
*
|
2010-08-06 |
2013-10-24 |
Kyorin Pharmaceutical Co Ltd |
ビシクロ[2.2.2]オクチルアミン誘導体の製造方法
|
EP2524694A1
(en)
|
2011-05-19 |
2012-11-21 |
Laboratorios Del. Dr. Esteve, S.A. |
Use of sigma ligands in diabetes type-2 associated pain
|
EP2530072A1
(en)
|
2011-06-03 |
2012-12-05 |
Lacer, S.A. |
New compounds, synthesis and use thereof in the treatment of pain
|
US9066853B2
(en)
|
2013-01-15 |
2015-06-30 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable fiber
|
ITMI20131757A1
(it)
|
2013-10-22 |
2015-04-23 |
Zach System Spa |
Processo di preparazione di gabapentina
|
DK3067430T3
(da)
|
2013-11-01 |
2020-09-21 |
Glytech Inc |
Fremgangsmåde til fremstilling af d-form-eller l-form-aminosyrederivat med en thiolgruppe
|
CA2933511A1
(en)
|
2013-12-17 |
2015-06-25 |
Laboratorios Del Dr. Esteve, S.A. |
Serotonin-norepinephrine reuptake inhibitors (snris) and sigma receptor ligands combinations
|
JP2017503765A
(ja)
|
2013-12-17 |
2017-02-02 |
ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ |
ガバペンチノイドおよびシグマ受容体の組み合わせ
|
WO2015144825A1
(en)
|
2014-03-27 |
2015-10-01 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Oral liquid pharmaceutical solution of gabapentin
|
PT3554490T
(pt)
|
2016-12-16 |
2022-03-17 |
Idorsia Pharmaceuticals Ltd |
Combinação farmacêutica compreendendo um bloqueador de canais de cálcio de tipo t
|
US11510903B2
(en)
|
2018-07-04 |
2022-11-29 |
Federico Amezcua Amezcua |
Synergic pharmaceutical composition of the active enantiomer (S)-ketorolac and Gabapentin for the treatment of neuropathic pain
|
US10399926B1
(en)
|
2018-08-01 |
2019-09-03 |
Divi's Laboratories Ltd. |
Process for the preparation of gabapentin
|
ES2754280A1
(es)
|
2018-10-11 |
2020-04-16 |
Laboratoris Sanifit S L |
Pautas posológicas de IP y análogos de IP para el tratamiento de calcificaciones ectópicas
|
WO2021079887A1
(ja)
|
2019-10-25 |
2021-04-29 |
国立大学法人京都大学 |
タウオパチーの予防又は治療剤
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|